Login / Signup

Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal Dementia.

Jennifer Hsiao-NakamotoChi-Lu ChiuLawren VandeVredeRitesh RaviBrittany VandenbergJack De GrootBuyankhishig TsogtbaatarMeng FangPaul AugerNeal S GouldFilippo MarchioniCasey A PowersSonnet S DavisJung H SuhJamal AlkabshHilary W HeuerArgentina Lario LagoKimberly Scearce-LevieWilliam W SeeleyBradley F BoeveHoward J RosenAmy BergerRichard TsaiGilbert Di PaoloAdam L BoxerAkhil BhallaFen Huangnull null
Published in: bioRxiv : the preprint server for biology (2024)
mutations. The observed correlations between biomarkers and disease severity open promising avenues for prognostic applications and for indicators of drug efficacy in clinical trials. Our data also implicated a complicated relationship between biofluid and tissue biomarker changes and future investigations should delve into the mechanistic underpinnings of these biomarkers, which will serve as a foundation for the development of targeted therapeutics for FTD.
Keyphrases
  • clinical trial
  • minimally invasive
  • small molecule
  • randomized controlled trial
  • emergency department
  • genome wide
  • late onset
  • gene expression
  • drug delivery
  • spinal cord
  • drug induced
  • spinal cord injury